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Summary Primary chemotherapy in operable breast invasive carcinoma enables tumour reduction and
conservative surgery. In order to search for one or more biological factors capable of predicting tumour
behaviour under primary chemotherapy, and subsequent patient survival, an immunohistochemical study was
performed with specific antibodies to p53, c-erbB-2 (Her-2/neu), Mibl (antiKi-67), pS2, GSTir, oestrogen
receptors (ERs) and progesterone receptors (PRs). Core biopsies, obtained before primary chemotherapy, were
available from a series of 128 breast invasive carcinomas treated between January 1985 and April 1989, with a
median follow-up of 93.3 months. Univariate statistical analysis showed that negative ER detection by
immunohistochemistry (IHC) was highly correlated with chemosensitivity (P=0.001). A high percentage of
Mibl-positive tumour cells (>40%), as well as initial tumour size less than 4 cm, were also correlated with
tumour responsiveness to chemotherapy (P=0.009 and P=0.03). By multivariate analysis IHC-ER, Mibl and
initial tumour size were independent predictors, the last parameter being the most important. Concerning
subsequent patient survival, c-erbB-2 overexpression, as detected by IHC, was significant with respect to overall
survival (OS) (P=0.0006), disease-free interval (DFI) (P=0.03) and metastasis-free interval (MFI) (P=0.008)
by univariate analysis. Furthermore, c-erbB-2 was the major independent prognostic factor for OS and MFI by
multivariate analysis.
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Since 1990 several reports have shown the effectiveness of
primary chemotherapy in breast conservative surgery of
resectable tumours larger than 3 cm (Bonnadonna et al.,
1990; Gazet et al., 1991; Mauriac et al., 1991; Belembaogo et
al., 1992; Calais et al., 1994; Smith et al., 1995). This new
therapeutic strategy, as well as those used in locally advanced
breast disease, requires the validation of clinical and
biological factors capable of predicting the tumoral response
to cytotoxic therapy, and the subsequent clinical outcome.
Until now most prognostic markers were designed and
validated on primary surgery series of breast invasive
carcinoma, complemented or not by adjuvant hormono- or
chemotherapy. In these series it is sometimes difficult to grasp
the meaning of the information provided by a prognostic
factor in relation to the response to adjuvant therapy once
the primary tumour has been removed. The primary
chemotherapy regimens are elegant in vivo models where
the informative value of a given tumour factor in relation to
a certain cytotoxic drug can be assessed by simply analysing
tumour shrinkage. Furthermore, the different criteria helping
the clinician to predict patient outcome are somewhat
different in the two therapeutic approaches, where one
major information source, e.g. histological assessment of
axillary lymph node involvement, is missing in the primary
chemotherapy group. Pretherapeutic tumour core biopsies
provide sufficient material to confirm the malignant and
infiltrative nature of a breast tumour as well as to study and
compare the predictive and prognostic values of different
immunohistochemical factors.
At Bergonie Institute we have conducted a clinical trial on
the effects of primary chemotherapy in conservative
treatment of breast invasive carcinoma (Mauriac et al.,
1991). A set of 134 core biopsies was at our disposal to
analyse different immunohistochemical factors including : the
products of a tumour-suppressor gene, p53; an oncogene; c-
erbB-2 (or Her-2/neu); a detoxifying agent, glutathione- S-
transferase pi (GSTm); a cell cycle nuclear protein, Ki67; an
oestrogen-regulated protein, pS2 and finally, oestrogen and
progesterone receptors. The aim of this study was to assess
their predictive value for tumour response to primary
chemotherapy and prognostic value for patient outcome
and compare them with classical clinical and biological
factors.
Materials and methods
Patient selection
Breast tumour core biopsies of 134 patients were retrieved
from the files of the pathology department of Institute
Bergonie and included in this immunohistochemical study.
These patients belonged to the chemotherapy arm of a
clinical trial on the effects of primary chemotherapy in
conservative treatment of breast invasive carcinoma. The
clinical trial was conducted at Bergonie Institute from
January 1985 to April 1989 and included a total of 272
women (for details see Mauriac et al., 1991). Briefly, the aim
of this trial was to compare initial surgery and primary
chemotherapy on primary metastasis-free operable breast
tumours larger than 3 cm.
Before randomisation, two samples were obtained from
each breast tumour. One sample was fixed in Bouin Hollande
and embedded in paraffin before histological analysis. For the
present study, six core biopsies of the initial 134 were
excluded because of insufficient residual material. In the other
sample oestrogen and progesterone receptor contents were
determined by the dextran-coated charcoal method (DCC),
with cut-off levels of 10 and 15 fmol mg-' of protein
respectively.
Primary chemotherapy consisted of six courses, three with
epirubicin, vincristine, methotrexate (EVM) followed by three
with mitomycin C, thiotepa and vindesine (MTV). After
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1996completion of the sixth course, clinical examination and a
radiographic mammogram were used to assess tumour
regression. Locoregional treatment depended on this para-
meter.
Exclusive radiotherapy was performed in the case of
complete regression. Conservative breast surgery with axillary
lymph node dissection followed by radiotherapy were done in
the cases of incomplete tumour regression with residual
tumour measuring less than 2 cm in diameter. Mastectomy
was performed in the remaining cases.
Histological examination was done on all excised tumours.
Thus, 128 core biopsies and 86 excised tumours are analysed
in this study.
Immunohistochemical assay
The IHC assays used in this study have been fully described
elsewhere (Soubeyran et al., 1995; de Mascarel et al., 1995).
Briefly, an antigen retrieval step was performed by heating
tissue sections in a citrate buffer. Two staining methods were
applied: a labelled streptavidin-biotin-peroxidase method
(LSAB Kit, Dako, France) (p53, c-erbB-2, GSTr, pS2) or an
avidin-streptavidin-biotin peroxydase method (Strept ABC
complex/HRP Duet Kit, Dako, France) (ER, PR, Mibl). The
following primary antibodies were applied: p53 [mouse
monoclonal DO7 (Dako, Trappes, France), dilution 1:100
in phosphate-buffered saline (PBS), 30 min at room
temperature]; c-erbB-2 [rabbit polyclonal (Dako), dilution
1: 600 in PBS, 10 min incubation at room temperature];
GSTi [rabbit polyclonal (a kind gift from Dr K Cowan,
NCI, Bethesda, MD, USA), dilution 1:3000 in PBS, 2 h
incubation at room temperature]; pS2 [mouse monoclonal
(CIS Bioindustries, France), dilution 1:10 in PBS, overnight
incubation at room temperature]; Mibl [mouse monoclonal
antiKi67 (Immunotech, France), dilution 1:100 in PBS, 1 h
incubation at room temperature]; ER [mouse monoclonal
clone lD5 (Dako), dilution 1: 25 in PBS, 45 min incubation
at room temperature]; PR [rat monoclonal clone PgR-ICA
(Abbott Inc), dilution 1:10 in PBS, overnight incubation at
room temperature].
Diaminobenzidine was used as chromogen. Haematoxylin
was used as counterstain for the c-erbB-2, GSTir, pS2 and the
Mibl assays, and light green was used as counterstain for the
p53, ER and PR assays. Concerning the Mibl assay, sections
were predigested in 0.1% trypsin, 0.4% calcium chloride in
PBS for 10 min before microwaving.
Scoring system
All the slides were scored by one of the authors (GMG).
For p53, Mibl, ER and PR, nuclear staining of invasive
tumour cells was scored as positive. For c-erbB-2,
membranous staining of invasive tumour cells was scored
as positive. For GSTx and pS2, cytoplasmic staining of
invasive tumour cells was scored as positive. The number of
positive cells per tissue section was determined semiquanti-
tively from 0% to 100%. The threshold for p53, c-erbB-2
and GSTir positivity, was 1%; for pS2 positivity, 3%; and
for IHC-ER and IHC-PR positivity, 10%. These optimal
thresholds have already been determined in previous studies
(MacGrogan et al., 1995; Quenel et al., 1995; Soubeyran et
al., 1995; de Mascarel et al., 1995) to be the most
informative for clinical outcome.
Statistical analysis
The chi-square test was used to investigate the significance of
the relationship between the different IHC markers, expressed
as dichotomised factors, and classical prognostic parameters,
e.g. histological grade, hormonal receptor status, as well as
the different IHC markers between themselves. The relation-
ship between the IHC factors and patients' age as well as
clinical tumour size was analysed by Student's t-test.
Differences in expression of IHC factors between the core
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biopsy and corresponding excised tumour after primary
chemotherapy were studied using a non-parametric rank-
sum sign test.
Relationship between the different factors and tumour
regression was determined in a univariate analysis by the log-
rank test using the Kaplan-Meier method. Interrelationship
between the different predictive factors was determined by
multivariate analysis using a logistic regression test. The
variable to predict was tumour reduction 50%, including
complete tumour remission. All factors were entered in the
logistic regression analysis whatever their P-value by
univariate analysis; but only those with a P-value < 1%
were kept in the final model.
The log-rank test using the Kaplan-Meier method was
again used to study the relationship between the different
factors and prognosis expressed as 5 year probability of
survival. A multivariate analysis using the Cox proportional
hazard model permitted statistical evaluation of the different
prognostic factors. All factors were entered in the Cox
regression analysis whatever their P-value by univariate
analysis; but only those with a P-value <1% were kept in
the final model.
Clinical size of the tumours was assessed before
treatment, before the second and fourth courses of
chemotherapy and at the sixth. Patient follow-up was done
quarterly for 2 years, twice a year and finally yearly. For
overall survival (OS), survival duration was calculated from
the randomisation date to death, or the date they were last
known alive. All causes of death were considered as events.
For metastasis-free interval (MFI) and for disease-free
interval (DFI), time to failure was computed from the
randomisation date until metastasis or relapse, or the date
they were last known to be disease-free respectively. For
DFI, local failure and/or metastasis were considered as
events. The cut-off date for the current analysis was 1 May
1995 with a median follow-up of 93.3 months. Univariate
analyses for survival were performed using the log-rank tests
and BMDP software, program IL. Multivariate analyses
were performed stepwise with the logistic regression or the
Cox regression models using BMDP 2L.
Results
Clinical, pathological and biological characteristics of this
series are listed in Table I. Distribution of patients in
treatment groups according to tumour response is shown in
Table II.
p53, c-erbB-2, Mibl, GSTi, pS2, IHC-ER, IHC-PR
expression in the series
Eighty-four out of 126 analysed cases (67%) and 72 out of
124 analysed cases (58%) were respectively ER positive and
PR positive by the IHC assay. Thirty-four (27%), 28 (22%)
and 94 (75%) out of 125 analysed cases were respectively
p53, c-erbB-2 and pS2 positive, and finally, 65 out of 126
analysed cases (52%) were GSTx positive by the IHC assay.
One hundred and twenty-three out of 125 core biopsies
contained Mibl-positive cells (97.7%). Mibl positivity ranged
from 3% to 90% oftumoral cells with a median value of20%.
A Mibl index of40%, corresponding to the 75th percentile in
the group, was arbitrarily chosen as threshold at the beginning
ofthe study to differentiate highly proliferating tumours from
the rest of the group. Twenty-seven cases (21.4%) had more
than 40% Mibl-positive tumour cells compared with 99
(78.6%) who had up to 40% Mibl positivity.
Relationship between the immunohistochemicalfactors and the
classical prognostic parameters
Age was respectively positively and negatively correlated with
IHC-ER and GSTr (P< 10-3 and P= 0.05). Initial clinically
assessed tumour size was respectively positively andImmunohistochemical factors and primary chemotherapy
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Table I Characteristics of patients and tumours
Clinicalfeatures
Mean age (range)
Menopausal status
Premenopausal
Perimenopausal
Post-menopausal
Mean tumour size (range)
TNM
T2
T3
NO
Pathologicalfeatures
Mean length of core biopsies
Histological type
IDC NOS
ILC
Mucinous carcinomas
SBR grade
1
2
3
53 years
(31 -69 years)
46
13
69
40 mm
(35-60mm)
101
27
62
(36%)
(10%)
(54%)
(79%)
(21%)
(48.4%)
11.8mn
(2-30 mm)
117
9
2
27
72
29
(91%)
(7%)
(2%)
(21%)
(56.3%)
(22.6%)
Biochemicalfeatures
Mean weight of samples (range) 36.6mg
(5 -98mg)
Mean protein concentration 42.1 mg protein
(range) per g of tissue
(16- 123mg
protein per g
of tissue)
Hormonal receptor status by
DCC methoda
ER-PR-
ER-PR+
ER+PR-
ER+PR+
57 (44.9%)
16 (12.6%)
24 (18.9%)
30 (23.6%)
IDC NOS, invasive ductal carcinoma not otherwise specified; ILC,
invasive lobular carcinoma; SBR, Scarff, Bloom and Richardson
grade; DCC method, dextran-coated charcoal method; ER, oestrogen
receptor status; PR, progesterone receptor status. aDCC.PR status
was not available for one patient.
Table II Clinical tumour response to primary chemotherapy and
secondary locoregional treatment
Secondary locoregional treatment
Tumour No. of Conservative Exclusive
response cases Mastectomy surgery radiotherapy
Progression 1 I
Stabilisation 9 9
Tumour
reduction
<50% 63 36 26
Tumour
reduction
>50% 13 1 12 -
Complete
regression 42 - - 42
aOne patient refused locoregional treatment.
negatively correlated with IHC-ER and pS2 (P = 0.05 and
P =0.04). Scarff, Bloom and Richardson (SBR) grade was
negatively correlated with IHC-ER (P = 7 x 10-4) and
positively correlated with p53, c-erbB-2 (Figure 1) and
Mibl (P=0.01, P=0.03 and P< l0-4 respectively). Con-
sidering each component of the SBR grade, none of the IHC
factors was correlated to tumour differentiation. Nuclear
grade was negatively correlated to IHC-ER, IHC-PR and pS2
(P< 10-4, P=0.02 and P=0.004 respectively), whereas
nuclear grade was positively correlated to p53, c-erbB-2,
Mibl (P =0.01, P =0.01 and P =0.01 respectively). There was
an inverse correlation between mitotic index and IHC-ER,
IHC-PR and pS2 (P= 0.02, P=0.05 and P=0.002 respec-
tively), and a positive correlation between the same index and
p53, c-erbB-2, Mibl and GSTir expression (P=0.02,
P=0.004, P< 10-4 and P=0.01 respectively). IHC-ER and
DCC-ER were highly correlated (P< 10-4), as well as IHC-
PR and DCC-PR (P< 10-4).
Relationship between the different IHCfactors
IHC-ER was negatively correlated with Mibl (P=0.01),
GSTir (P= 0.01) and positively correlated with pS2 (P< 10-4)
and IHC-PR (P< 10-4). IHC-PR was negatively correlated
with c-erbB-2 (P=0.01) and positively correlated with pS2
(P<10-4).
Predictive value of the classical and IHCfactors
By univariate analysis, IHC-ER (Figures 2a and 3), Mibl
(Figure 4) and initial clinical tumour size (Figure 5)
significantly correlated with chemotherapeutic induced
tumour regression >50%, including complete tumour
regression (P=0.001, P=0.009 and P=0.03 respectively).
The rest of the factors including SBR grade, mitotic index,
nuclear grade, tumour differentiation, DCC-ER, DCC-PR,
p53, c-erbB-2, GSTir, pS2 and IHC-PR were not significantly
correlated with tumour response.
Twelve parameters were included in the stepwise logistic
regression test, e.g. tumour size >40 mm, SBR grade 3, SBR
grade 1, IHC-ER <10%, IHC-PR <10%, DCC-ER
< 10 fmol mg-', DCC-PR < 15 fmol mg-', Mibl >40%,
pS2 <3%, p53 <0%, c-erbB-2 <1% and GSTx <1%.
Pretherapeutic clinically assessed tumour size was the most
important independent factor in predicting a tumour
regression >50%, including complete regression. IHC-ER
and Mibl index were the other independent informative
parameters (Table III).
Difference in expression ofIHC markers in the core biopsy and
corresponding excised tumour after primary chemotherapy
The rank-sum sign test suggested an increase in the
expression of p53 and GST7r in the tumour after
chemotherapy (P=0.01 and P=0.03) and a decrease in the
expression of c-erbB-2, pS2 and IHC-PR (P=0.008,
P<0.001 and P=0.007 respectively). No significant differ-
ence in expression was found for Mibl and IHC-ER.
Prognostic value of the classical and IHCfactors
In a univariate analysis, the relationships between OS, DFI,
MFI and initial tumour size, SBR grade, DCC-ER, DCC-
PR, p53, c-erbB-2, Mibl, GSTh, pS2, IHC-ER, IHC-PR
status, tumour response (tumour reduction <50% and
tumour reduction >50%, including complete remission)
and treatment (e.g. exclusive radiotherapy, conservative
surgery and radiotherapy, mastectomy) were assessed.
C-erbB-2 was highly significant with respect to OS
(P=0.0006), DFI (P=0.03) and MFI (P=0.008). IHC-PR
and DCC-PR were significant with respect to OS (P=0.05
and P=0.03) and Mibl was significant with respect to MFI
(P=0.05) (Table IV). No other significant correlation was
found with survival and the rest of the studied parameters,
including tumour response to primary chemotherapy and
treatment modality.
Twelve parameters were included in the Cox multivariate
analysis, e.g. tumour size >40 mm, SBR grade 3, SBR grade
1, IHC-ER <10%, IHC-PR <D10%, DCC-ER
< 10 fmol mg-', DCC-PR < 15 fmol mg-', Mibl <40%,
pS2 <3%, p53 >0%, c-erbB-2 >0% and GSTr <1%. The
final model only included c-erbB-2 >0% as an independent
prognostic factor with regard to OS [relative risk=2.4 (1.15-
4.3) P=0.01] and MFI [relative risk=2.5 (1.1-4) P=0.01].
No independent prognostic factor for DFI with a significant
P-value was found in this group by multivariate analysis.Immunohistochemical factors and primary chemotherapy
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Figure 1 Immunohistochemical staining of c-erbB-2 in a pretherapeutic core biopsy of an infiltrating ductal carcinoma.
Semiquantitative score ofpositive tumoral cells equal to 100%. Haematoxylin counterstain ( x 400) (a). Corresponding haematoxylin
and eosin safran stain (b) showing SBR grade 3 features ( x 400).
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and 800o respectively. (a), light green counterstain ( x 400). (b), haematoxylin counterstain ( x 400).
I
ssf,
9
s
10
M
I
V
p
'I _lr 1-Cl,---'--- A-- -1-Immunohistochemical factors and primary chemotherapy
G MacGrogan et al
1462
(44)
(4
IHC-ER positive
(32.7)
(35.4)
(25.1)
(15.2)
IHC-ER negative
P= 0.001
1 2 3 4
Chemotherapy courses
5 6
Figure 3 Tumour shrinkage during the six courses of primary
chemotherapy. Comparison between the IHC-ER-positive and
IHC-ER-negative groups (mean size of tumours).
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P = 0.009
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Figure 4 Tumour shrinkage during the six courses of primary
chemotherapy. Comparison between the highly proliferating
tumours (Mibl>40%) and the rest of the group (Mibl 40%)
(mean size of tumours).
- (50.3)
(43.7) Initial tumour size
(37.6) ~~~>40 mm - (37.6) (36.6)
A (1.6) )
(24.7)
_ ~~~(18.4)
Initial tumour size
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P=0.03
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Figure 5 Tumour shrinkage during the six courses of primary
chemotherapy. Comparison between the large tumour (>40mm)
and small tumour (,<40mm) groups (mean size of tumours).
Table III Independent predictive factors for response to primary
chemotherapy (tumour regression>50% and complete regression)
Relative risk P-valuea
1 Tumour size <40mm 3.88 (1.6-9.3) 0.003
2 IHC-ER<10% 3.29 (1.4-7.6) 0.005
3 Mibl>40% 4.12 (1.4-11.5) 0.007
aGlobal P-value for the model: P=0.004. Multivariate analysis
(logistic regression).
Discussion
This study was designed to evaluate and compare the
predictive values of classical prognostic factors and new
IHC markers for breast carcinoma treated by primary
chemotherapy. Because of the novelty of this approach and
the relatively high number of prognostic factors studied, it
should be considered as a phase II prognostic factor study as
defined by Simon and Altman (1994). Results presented here
apply to this particular population of patients treated by a
specific chemotherapeutic regimen, and confirmatory studies
are required to apply any generalisation.
Predictive value of 'tumour size'
Our results confirm previous reports (Bonadonna et al.,
1990) in which small tumours (,<40 mm) responded better
than large tumours (>40 mm). Initial, clinically assessed
tumour size was a major factor in predicting tumour
response to chemotherapy. This is in accordance with the
Gompertzian model of tumour growth, in which large
tumours contain fewer proliferating cells than small
tumours and, therefore, do not respond as well to the
same dose of chemotherapy. However, almost similar
tumour shrinkage curves were observed between the large
tumour group (>40 mm) and the small tumour group
(<,40 mm). If, after six cycles of chemotherapy, small
tumours had shrunk more than 50% of initial tumour size
(Figure 5), with three more cycles, large tumours may have
achieved the same goal. Further studies are required to
verify this hypothesis.
Predictive value of 'hormone receptor status'
The results of this study indicate that IHC detection of
oestrogen receptors in breast carcinoma is also of major
importance in determining tumoral response to primary
chemotherapy. This is in accordance with previous reports
showing a weak but significant link between ER-DCC status
and tumoral chemosensitivity (Bonadonna et al., 1990;
Mauriac et al., 1991; Belemboago et al., 1992). In this study
the predictive power of IHC-ER was much more important
than that of DCC-ER concerning tumour regression
(P=4x 10-4 vs P=0.1). Although the IHC and DCC-ER
assays were highly correlated (P< 10-4), more ER-positive
tumours were found by the IHC assay compared with the DCC
assay (67% vs 46%). This may be explained by differences in
tumour sampling, since the IHC-ER assay was performed on
theparaffin tissue blockcontaining the core biopsy in which the
pathological diagnosis of invasive carcinoma was initially
made, while the only control to confirm the presence of
invasive carcinoma in the core biopsy sent for DCC-ER assay
was done by cytological imprinting. Low tumour cellularity as
well as low protein concentration of DCC-analysed samples
may also explain the existance ofDCC-ER-negative/IHC-ER-
positive cases. This high rate ofnegative DCC-ER results with
subsequent poor predictive value of DCC-ER may partially
explain why previous studies did not find a relationship
between DCC-ER and tumour regression.
In vitro and clinical studies have shown the increased
sensitivity of ER-negative tumour cell lines and tumours
towards cytotoxic agents, especially doxorubicin (Kaufman et
al., 1980; Livingston et al., 1982; Mortimer et -al., 1985).
Epirubicin, a derivative of doxorubicin, was used in our
study. ER-negative tumours have higher proliferation indexes
than ER-positive tumours (Silvestri et al., 1979; Meyer et al.,
1979) and should, therefore, be more chemosensitive. We
found that, even if IHC-ER was negatively correlated with
Mibl index (P=0.01), IHC-ER was still an important
independent factor in predicting tumour chemosensitivity,
suggesting an independent effect, other than proliferative
activity, in ER-negative tumours.
In our series PR status was not predictive for immediate
tumour response to chemotherapy, but predicted subsequent
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Table IV Prognostic value of classical and IHC factors, after primary chemotherapy in breast invasive carcinoma
No. of
cases Os (%) P-value DFI (%) P-value MFl (%) P-value
Global 128 78.1 58.6 67.2 Tumour size (mm)
<40
>40
SBR grade
1
2
3
DCC-ER
<10
>10
DCC-PR
<15
91.3 65.2
79.1 NS (0.9)
76.5
82.5 0.0006
64.3
77.8 NS (0.4)
61.5
71.7
NS (0.6)
50
62.9 0.04
39.3
56.6
68.1 NS (0.9)
61.8
72.2 0.008
46.4
NS (0.4) 63.6 0.05
81.5 63
83.6 NS (0.8)
73.8
74.2 NS (0.8)
57.4 NS (0.3)
60
54.8 NS (0.9)
77.8
67.2 NS (0.3)
66.2
67.7 NS (0.9)
80.9 59.6
71.4 NS (0.1) 57.1 NS (0.9)
59.5 70.2
51.9 NS (0.1)
62.5
65.4 NS (0.5)
68.1
Univariate analysis (log-rank test). Five year probability of survival.
interval; NS, not significant.
OS, overall survival; DFI, disease-free interval; MFI, metastasis-free
OS. Previous reports have shown the prognostic value of PR
after adjuvant chemotherapy in breast cancer (Raemakers et
al., 1987).
Predictive value of 'proliferative index'
We only found a significant difference in clinical response to
primary chemotherapy in highly proliferating tumours
showing a Mibl index over 40%. This observation confirms
previous in vitro studies showing an increased sensitivity of
highly proliferating tumours towards cytotoxic drugs in
breast carcinoma cell lines (Weichselbaum et al., 1978;
Tannock et al., 1978; Drewinko et al., 1981). Similarly,
previous clinical trials assessing S-phase fraction by flow
cytometry demonstrated better clinical response to primary
chemotherapy in tumours showing a high S-phase fraction
(Spyratos et al., 1992; O'Reilly et al., 1992; Belemboago et
al., 1992; Remvikos et al., 1993). Surprisingly, the few clinical
trials using the tritiated thymidine labelling index (TLI) as a
method of assessing tumour proliferation did not show a
significant difference for tumour response in tumours with a
high TLI (Bonadonna et al., 1990; Daidone et al., 1991;
Gardin et al., 1994). These differences may result in the small
number of cases included in these series. Considering clinical
outcome, patients with a high Mibl index had 5 year
metastasis-free estimates significantly higher than those
patients with a Mibl index less than 40% (P=0.05).
Conflicting results are reported in the literature. Elevated S-
phase fractions before neoadjuvant chemotherapy correlated
with a higher relapse frequency in the series of Spyratos et al.
(1992). The series studied was small (35 patients with short-
term follow-up). In another report by Stil et al. (1994),
patients with highly proliferating tumours benefited from
adjuvant chemotherapy compared with those with slowly
growing tumours.
Predictive value of 'c-erbB-2 overexpression'
Chemosensitivity and overexpression of c-erbB-2 in human
breast carcinoma is a matter of controversy (for review see
Klijn et al., 1993). In our series c-erbB-2 was not a predictive
factor for chemotherapeutic-induced tumour reduction or
tumour resistance. On the other hand, c-erbB-2 was a major
independent marker for predicting subsequent OS and MFI;
patients overexpressing c-erb-2 having worse prognosis. These
results are in accordance with those of other studies on
adjuvant chemotherapy in node-positive breast carcinoma
patients (Allred et al., 1992; Gasparini et al., 1992), but
contradict those of Muss et al. (1994). These authors showed
that patients overexpressing c-erbB-2 had better survival rates
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(0.2)
-
63.9
70.9
85.2
61.1
65.5
69.9
63.6
65.4
46
NS
(0.8)
NS
(0.15)
NS
(0.85)
NS
(0.4)
>1
c-erbB 2
<0
91
34
97
>1
Mibl
<40
28
>40
GSTh
<0
99
27
61
>1
pS2
<3
65
31
>3
IHC-ER
<10
94
>10
IHC-PR
<10
42
84
52
83.3
75
67
72
0.03
84.7
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than those not overexpressing c-erbB-2 under high dose
polychemotherapy including doxorubicin. Cytotoxic drugs in
our study were given at conventional doses and it may well
be that because of that we did not see a benefit of
chemotherapy in patient3 overexpressing c-erbB-2.
Predictive value of 'P53, pS2 and GST7r'
p53 expression was not related to tumourchemoresistance or to
subsequent survival. Although it has been hypothesised that
p53 tumour mutation could be a significant factor in
chemosensitivity or chemoresistance. Our data do not support
either hypothesis. However, an increase in p53 expression was
observed in surgically removed tumours (P=0.009), rank-sum
sign test). Rasbridge et al. (1994) reported a similar
observation. This increase in p53 expression could either
reflect secondarily acquired p53 mutations in resistant
tumours or a physiological response of tumour cells towards
chemotherapeutic-induced genomic damage.
An increase in expression of GSTh was observed in
surgically removed tumours (P=0.03, rank-sum sign test),
confirming previous in vitro studies (Whelan et al., 1989;
Whelan and Hill, 1993) in which GSTx expression was shown
to be increased in human cytotoxic drug-resistant cell lines,
reflecting its cytoplasmic detoxifying function.
Conversely, a decrease in the expression of pS2 (P<0.001
rank-sum sign test), as well as that of IHC-PR (P=0.007),
was evidenced in surgically removed tumours. These two
proteins, whose expression is regulated by oestrogens, are the
sign of functional oestrogen receptors, when present in breast
tumours. Recently Whelan et al. (1992) showed a loss of
detectable pS2, PR and heat shock protein 27 (hsp 27) in
MCF-7 sublines exhibiting a multidrug resistance phenotype.
In our series, if no significant variation in the expression of
IHC-ER was observed after chemotherapy, the ER detected
seemed to have lost functional activity.
Predictive value of 'SBR grade'
Surprisingly, in our series no significant predictive informa-
tion was given by the assessment of tumour grade on the core
biopsy before chemotherapy, even though SBR grade was
correlated with major parameters in the series (Mibl,
c-erbB-2 and IHC-ER). These results differ from those of
another report on neoadjuvant chemotherapy (Jacquillat et
al., 1990), showing that tumour grading helps in assessing
tumour chemosensitivity. But in the latter report, it is not
clear whether tumour grading was histological or cytological
or a combination of both. In our experience, SBR grading is
one of the most important prognostic factors for predicting
OS, MFI and DFI in node-negative and positive patients, in
surgically removed, primary, metastasis-free, breast carcino-
ma (MacGrogan et al., 1995). The size of the core biopsies
analysed in this series was relatively small (mean length of
11.8 mm) making grading less comfortable than examining
the entire section of a surgical tumour specimen. This is
particularly true for assessment of mitotic index, which is
usually done by us by counting the maximum number of
mitoses in ten high-power fields (HPFs). In some cases in our
series, ten HPFs of assessable invasive carcinoma were not
available on the core biopsy analysed. In these cases mitotic
index was predicted from the maximum number of mitoses
counted in one field.
Predictive value of 'tumour response'
Neither tumour response to primary chemotherapy nor local
treatment were correlated with subsequent patient outcome in
our series, in contrast to other reports (Feldman et al., 1986;
Jacquillat et al., 1990; Scholl et al., 1991; Calais et al., 1994).
Ideally, tumour regression should have been confirmed by
microscopic analysis, but this was impossible, because of the
construction of our clinical trial. Feldman et al. (1986)
performed a macroscopic as well as a microscopic analysis on
all tumours and lymph nodes in their series. They found that
absence ofmacroscopic evidence ofresidual gross cancer was a
better indicator of improved survival than clinically assessed
complete response. However, they did not use mammography
to complement clinical examination. Furthermore, Feldman et
al. (1986), as well as Jacquillat et al. (1990), included in their
series inflammatory breast cancers for which clinical presenta-
tion and outcome differ from non-inflammatory breast cancers.
The chemotherapy regimen in our series was identical for all
patients, and was performed only initially. In the other series
chemotherapeutic protocols are either heterogeneous, or
sometimes complemented by hormone therapy or performed
before and after surgery or radiotherapy.
Conclusion
In breast carcinoma, new therapeutic regimens are at the
clinician's disposal for reducing tumour size before surgery in
order to prevent mastectomy. New laboratory tools must be
designed, in this perspective, that are capable of predicting
tumour behaviour and patient survival. In this series of 128
core biopsies, we have shown that clinical measurement of
tumour size, IHC assessment of ER content and determina-
tion of Mibl index before primary chemotherapy in breast
invasive carcinomas, are major indicators of tumour
chemosensitivity or resistance. Furthermore, detection of
c-erbB-2 overexpression is the best prognostic factor for
subsequent survival in patients treated by primary che-
motherapy.
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